Скачать с ютуб Endometrial Cancer Treatment FDA Approved - Dr Robert DeBernardo, MD в хорошем качестве

Endometrial Cancer Treatment FDA Approved - Dr Robert DeBernardo, MD

For More Videos Like this Subscribe to the OncologyTube Newsletter: https://share.hsforms.com/1dpwSptdCQP... In this video, Dr. Robert DeBernardo, MD, from Cleveland Clinic, discusses the recent FDA approval of dostarlimab-gxly (Jemperli) for the treatment of advanced or recurrent endometrial cancer. Previously approved only for patients with mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) tumors, dostarlimab-gxly's indication has now been expanded to include all patients with this type of cancer, regardless of their MMR status. Dr. DeBernardo highlights the significance of this expansion, explaining how the RUBY trial demonstrated substantial benefits in overall survival and progression-free survival when immunotherapy was added to the standard chemotherapy regimen. He also discusses the broader impact of this approval, making advanced treatments more accessible and setting a new standard of care. Additionally, Dr. DeBernardo addresses potential side effects associated with immunotherapy, such as thyroid dysfunction, myositis, and other immune-mediated toxicities, and offers advice on managing these reactions. This expansion represents a major advancement in the treatment of endometrial cancer, providing new hope for patients and healthcare providers alike. Timestamps: 0:00 - Introduction to the expanded FDA approval 0:30 - Overview of the RUBY trial results 1:30 - Importance of immunotherapy in endometrial cancer 2:00 - Managing potential side effects of immunotherapy Tags: #EndometrialCancer #FDAApproval #Dostarlimab #Immunotherapy #CancerTreatment #Oncology #ClevelandClinic #DrRobertDeBernardo #Jemperli #CancerResearch